|Covidien Launches Campaign to Increase Awareness of Pregnancy-Related Blood Clots|
New “1 in 1,000” campaign helps healthcare professionals educate patients about VTE risks
“1 in 1,000” refers to the number of women who are likely to experience a potentially life-threatening blood clot during pregnancy, delivery or postpartum. These blood clots, called venous thromboembolism (VTE), encompass both deep vein thrombosis and pulmonary embolism.
“The increased incidence of VTE during pregnancy and the peripartum period warrants special consideration and preventive intervention,” said
Developed in consultation with leading women’s health experts, the “1 in 1,000” education and prevention program focuses on empowering healthcare professionals to take action against VTE. The program includes guidelines and materials on how to educate pregnant patients on the risks of VTE and highlights the importance of appropriate VTE risk assessment - as well as prevention protocols at hospitals and health systems. The Association of periOperative Registered Nurses (AORN) awarded its Seal of Recognition for “1 in 1,000” campaign program components. Additional program information and materials can be accessed at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.covidien.com%2F1in1000&esheet=50324654&lan=en-US&anchor=www.covidien.com%2F1in1000&index=3&md5=1afa0a02c3344cfd4c786cec305830c8.
“Research shows that pregnant women are at four to five times’ greater risk for developing a potentially life-threatening VTE than non-pregnant women,2” said
In pregnant women, the likelihood of VTE onset heightens during delivery and the immediate postpartum period. Physiologic and anatomic changes during pregnancy increase a woman’s risk for VTE,3 and having a Cesarean delivery (C-section) nearly doubles that risk.4 Other risk factors include personal or family history of clotting disorders, pregnancy-induced hypertension, age greater than 35, obesity, race and smoking, among others.5
1. Chang J, Elam-Evans LD, Berg CJ, Herndon J, Flowers L, Seed KA, et al. Pregnancy-related mortality surveillance—United States, 1991–1999. MMWR Surveill Summ 2003; 52:1–8.
2. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005;143:697–706.
3. Gordon MC. Maternal physiology. In: Gabbe SG, Niebyl JR and
4. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. Scott Med J 1996;41:83–6.
5. James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006;194:1311–5.
6. Thromboembolism in pregnancy. Practice Bulletin No. 123.